Trials / Completed
CompletedNCT03117101
Study of the AL3810 in the Treatment of Advanced Solid Tumor
An Open-label, Dose-finding Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, Pharmacodynamics of the Dual -VEGFR-FGFR Tyrosine Kinase Inhibitor, AL3810, Givenorally as Single Agent to Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Haihe Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study
Detailed description
Methodology: This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study with a traditional 3+3 design, conducted in Chinese patients with advanced solid tumours without an established therapeutic alternative.This study was performed in strict accordance with Good Clinical Practice including the archiving of essential documents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lucitanib |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2017-04-17
- Last updated
- 2017-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03117101. Inclusion in this directory is not an endorsement.